Clinical bottom line
Severe aortic regurgitation (AR) presents unique anesthetic challenges during non-cardiac surgery due to the risk of hemodynamic instability from volume overload and left ventricular dysfunction. Current evidence on anesthetic management and outcomes in this population is limited and largely extrapolated from studies of aortic valve disease and surgical correction cohorts. Careful perioperative assessment, maintenance of preload and afterload balance, and avoidance of tachycardia are critical. However, robust prospective data specifically addressing anesthetic strategies and outcomes in severe AR patients undergoing non-cardiac surgery remain sparse, warranting cautious individualized management.
What the evidence shows
Severe AR leads to volume overload of the left ventricle, which can result in compensatory dilation and eventual systolic dysfunction if untreated. The anesthetic goal is to maintain adequate preload, avoid increases in afterload, and prevent tachycardia that shortens diastolic filling time and coronary perfusion. While direct evidence on anesthetic management in severe AR during non-cardiac surgery is limited, insights can be drawn from related valve disease studies and surgical cohorts.
Higuchi et al. (2020) examined predictors of futility in transcatheter aortic valve implantation but focused primarily on aortic stenosis rather than regurgitation, highlighting the paucity of data on AR-specific interventions. Del Forno Benedetto et al. (2022) studied the fate of moderate secondary mitral regurgitation after aortic valve replacement for severe AR, underscoring the complex valvular interplay and the importance of comprehensive cardiac evaluation preoperatively.
Patients with surgically corrected congenital heart defects, such as D-transposition of the great arteries, provide some perioperative anesthetic outcome data for complex valvular and ventricular physiology during non-cardiac surgery (Author et al., 2010). These data emphasize the need for multidisciplinary planning and vigilant intraoperative monitoring.
Although much of the literature focuses on aortic stenosis, the principles of hemodynamic management—avoiding hypotension and tachycardia—are relevant for AR. Omoto Tadashi et al. (2020) demonstrated improved outcomes in severe aortic stenosis patients undergoing non-cardiac surgery after transcatheter valve replacement, suggesting that correction of valve pathology before elective surgery may optimize perioperative risk, a concept potentially applicable to severe AR patients.
Caveats and uncertainty
No large prospective trials or randomized controlled studies specifically address anesthetic management or outcomes in severe AR patients undergoing non-cardiac surgery. Most evidence is extrapolated from aortic stenosis cohorts or surgical valve replacement populations, which differ pathophysiologically from AR.
The heterogeneity of AR severity, ventricular function, and comorbid valvular lesions complicates generalization. Additionally, the impact of newer transcatheter therapies for AR on perioperative risk is not well defined, unlike the more extensively studied aortic stenosis interventions.
The role of invasive hemodynamic monitoring and the optimal anesthetic agents for this population remain areas of clinical judgment rather than evidence-based consensus. Furthermore, the influence of concomitant mitral regurgitation or other valvular disease on anesthetic risk in AR patients requires further elucidation.
How this may change practice
Clinicians should maintain a high index of suspicion for hemodynamic instability in severe AR patients presenting for non-cardiac surgery. Preoperative cardiac evaluation should include assessment of left ventricular size and function, degree of regurgitation, and presence of secondary valvular lesions.
Where feasible, correction of severe AR via surgical or transcatheter approaches prior to elective non-cardiac surgery may reduce perioperative risk, extrapolating from data in aortic stenosis populations (Omoto Tadashi et al., 2020). Intraoperative management should prioritize maintenance of preload, avoidance of systemic hypertension, and prevention of tachycardia, with readiness for invasive monitoring and vasoactive support.
Multidisciplinary collaboration involving cardiology, anesthesiology, and surgery is essential for individualized risk stratification and planning. Further research is needed to define optimal anesthetic protocols and to clarify the impact of emerging valve therapies on perioperative outcomes in this population.